Evidence map›Paper›PMID 33956375›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2021

Mutagenesis and homology modeling reveal a predicted pocket of lysophosphatidylcholine acyltransferase 2 to catch Acyl-CoA.

Fumie Hamano, Kazuaki Matoba, Tomomi Hashidate-Yoshida, Tomoyuki Suzuki, Kiyotake Miura, Daisuke Hishikawa, Takeshi Harayama, Koichi Yuki, Yoshihiro Kita, Nobuo N Noda and 2 more

Open access · greenAbstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Mutagenesis and homology modeling reveal a predicted pocket of lysophosphatidylcholine acyltransferase 2 to catch Acyl-CoA.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Fumie HamanoDepartment of Lipid Signaling, National Center for Global Health and Medicine, Tokyo, Japan.
Kazuaki MatobaInstitute of Microbial Chemistry (BIKAKEN), Tokyo, Japan.
Tomomi Hashidate-YoshidaDepartment of Lipid Signaling, National Center for Global Health and Medicine, Tokyo, Japan.
Tomoyuki SuzukiDepartment of Lipid Signaling, National Center for Global Health and Medicine, Tokyo, Japan.
Kiyotake MiuraDepartment of Biochemistry and Molecular Biology, The University of Tokyo, Tokyo, Japan.
Daisuke HishikawaDepartment of Lipid Signaling, National Center for Global Health and Medicine, Tokyo, Japan.
Takeshi HarayamaDepartment of Lipid Signaling, National Center for Global Health and Medicine, Tokyo, Japan.
Koichi YukiDepartment of Biochemistry and Molecular Biology, The University of Tokyo, Tokyo, Japan.
Yoshihiro KitaLife Sciences Core Facility, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Nobuo N NodaInstitute of Microbial Chemistry (BIKAKEN), Tokyo, Japan.
Takao ShimizuDepartment of Lipid Signaling, National Center for Global Health and Medicine, Tokyo, Japan.
Hideo ShindouDepartment of Lipid Signaling, National Center for Global Health and Medicine, Tokyo, Japan.
National Center for Global Health and Medicine · JPMicrobial Chemistry Research Foundation · JPThe University of Tokyo · JPHarvard University · USTokyo Medical and Dental University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Platelet-activating factor (PAF) is a potent proinflammatory phospholipid mediator that elicits various cellular functions and promotes several pathological events, including anaphylaxis and neuropathic pain. PAF is biosynthesized by two types of lyso-PAF acetyltransferases: lysophosphatidylcholine acyltransferase 1 (LPCAT1) and LPCAT2, which are constitutive and inducible forms of lyso-PAF acetyltransferase, respectively. Because LPCAT2 mainly produces PAF under inflammatory stimuli, understanding the structure of LPCAT2 is important for developing specific drugs against PAF-related inflammatory diseases. Although the structure of LPCAT2 has not been determined, the crystal structure was reported for Thermotoga maritima PlsC, an enzyme in the same gene family as LPCAT2. Here, we identified residues in mouse LPCAT2 essential for its enzymatic activity and a potential acyl-coenzyme A (CoA)-binding pocket, based on homology modeling of mouse LPCAT2 with PlsC. We also found that Ala115 of mouse LPCAT2 was important for acyl-CoA selectivity. In conclusion, these results predict the three-dimensional (3D) structure of mouse LPCAT2. Our findings have implications for the future development of new drugs against PAF-related diseases.

Indexed as

Models, MolecularMutation1-Acylglycerophosphocholine O-AcyltransferaseAcyl Coenzyme AAmino Acid SequenceAnimalsCatalytic DomainMiceMolecular Dynamics SimulationMutagenesis, Site-DirectedProtein ConformationSequence Homology1-Acylglycerophosphocholine O-AcyltransferaseAcyl Coenzyme ALPCAT2 protein, mouseAGPAT familyLPCAT1LPCAT2platelet activating factorprotein structure

Identifiers

PMID33956375
PMCPMC12315963
OpenAlexW3157955695

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.